Document is current
Any future updates will be listed below
-
Authors
Saviano, Antonio https://orcid.org/0000-0001-7585-472X
Toso, Alberto
Klempner, Samuel J. https://orcid.org/0000-0002-4062-0808
Baumert, Thomas F. https://orcid.org/0000-0002-8864-2168
- License Information
-
More Information
Article History
Accepted: 26 January 2026
First Online: 2 March 2026
Competing interests
: Inserm, the University of Strasbourg, the Strasbourg University Hospitals, Alentis Therapeutics at the IHU Strasbourg have filed patent applications for the use of anti-CLDN1 monoclonal antibodies for the treatment of fibrosis and cancer (T.F.B., A.T. and A.S. co-inventors), which have been licensed to Alentis Therapeutics. T.F.B. is founder, shareholder and adviser of Alentis Therapeutics. A.T. is employee and holds shares in Alentis Therapeutics. A.S. has served as consultant for Abbvie and Gilead. S.J.K. has served a consultant/advisory role for Bristol Myers Squibb, Merck, Astellas, Daiichi-Sankyo, Natera, Novartis, AstraZeneca, Mersana, Beigene, Gilead, Elevation Oncology, EsoBiotec, Eisai, Taiho, Boehringer-Ingelheim and I-Mab. S.J.K. reports research support (institutional) from AstraZeneca, I-Mab, Arcus Biosciences, Mersana, Parabilis, the Torrey Coast Foundation, the Degregorio Foundation, the Gastric Cancer Foundation, Debbie’s Dream Foundation, NIH/NCI, StandUp2Cancer and AACR. S.J.K. serves (uncompensated) on the NCCN guidelines for gastric and oesophageal cancers and the medical advisory board for Debbie’s Dream Foundation.
